-Bloomberg
Humanigen, Cenexi Ink Manufacture Pact For COVID-19 Candidate, Lenzilumab, In France
Humanigen Inc (NASDAQ: HGEN) has selected Cenexi as a preferred supplier of lenzilumab in France and the European Union.
Related Posts
GDS Clocks 10% Topline Growth In Q4 Backed By Net New Bookings; Updates On International Expansion
GDS Holdings Ltd (NASDAQ:GDS) reported fourth-quarter FY22 net revenue growth of 9.9% year-on-year to $348.6 million, beating the consensus of…
Roblox Nov. DAUs 56.7M, Up 15% YoY, Hours Engaged 3.9B, Up 10% YoY; Est. Revenue $190M-$193M, Est. Bookings $222M-$225M, Est Avg. Bookings Per DAU Down 7-9%
Daily active users (DAUs) were 56.7 million, up 15% year-over-year.
Hours engaged were 3.9 billion, up 10% year-over-year.
Estimated revenue was between $190 million and $193
Why Are Tegna Shares Trading Higher Premarket Tuesday?
Apollo Global Management Inc (NYSE:APO) and Standard General collaboratively made a bid topping $8 billion for the local TV…